CIELO: a randomized, double-blind, placebo-controlled, phase 3 basket study of satralizumab in patients with NMDAR- or LGI1-antibody encephalitis
Autori principali: | , , , , , , , , , , |
---|---|
Natura: | Conference item |
Lingua: | English |
Pubblicazione: |
Wiley
2022
|